Redundant medication use during acute exacerbation of chronic obstructive pulmonary disease in hospitalized patients
- PDF / 564,662 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 193 Views
RESEARCH ARTICLE
Redundant medication use during acute exacerbation of chronic obstructive pulmonary disease in hospitalized patients Ryan Dull1,2,3 · Stacey Dull1,2 Received: 11 February 2020 / Accepted: 21 May 2020 / Published online: 20 September 2020 © Springer Nature Switzerland AG 2020
Abstract Background Few clinical studies have evaluated redundant therapy during an exacerbation of chronic obstructive pulmonary disease in hospitalized patients, but clinical practice guidelines endorse this practice. Objective The aim of this study is to measure the frequency of redundant therapy and explore its association with clinical outcomes, adverse effects, and cost among adults hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Setting Six hospitals within an academic health system in the United States. Method A retrospective cohort study of adults with a principal diagnosis of acute exacerbation of chronic obstructive pulmonary disease between January 1, 2016 and March 31, 2016 was performed. Main outcome measure The primary outcome was the proportion of patients who received redundant therapy during inpatient management of acute exacerbation of chronic obstructive pulmonary disease. Results Overall, 137 patients were included and 99 (72.7%) received redundant medication therapy. Redundant therapy was not associated with significant differences in clinical outcomes such as median hospital length of stay, 30-day readmission, tachycardia, thrush, psychiatric symptoms or urinary retention in the univariate or multivariate analyses. The median medication acquisition cost per patient was nearly 11-fold higher among those receiving redundant medication therapy [$135.14 (49.21) vs 12.50 (17.02); p
Data Loading...
